Stock Movers: USA Rare Earth, CoreWeave, GameStop Gainers; Booze Allen, Trade Desk, Revolution Medicines Decliners

Market Performance Overview

• 📈 The US market saw upward momentum, with 317 names in the S&P 500 higher on a snowy Monday.
• 📊 Sectors like communication services, tech, utilities, and financials led gains, while consumer discretionary, consumer staples, and real estate finished slightly in the red.

Rare Earths and AI Chip Investments

• 💡 USA Rare Earth rallied nearly 8% on news of a non-binding agreement with the Commerce Department for $1.6 billion in funding to boost domestic rare-earth production.
• ⚠️ Other rare earth companies like MP Materials and Lithium Americas saw initial rallies but later sold off, with analysts noting USA Rare Earth is in early stages and the agreement is non-binding.
• 🚀 CoreWeave shares rose 5.7% after Nvidia invested an additional $2 billion in the cloud computing firm, aiming to expand AI computing capacity.
• 💰 Nvidia's investment in CoreWeave, a key customer, highlights the trend of circular financing in the AI sector.

Notable Stock Gainers

• 💎 GameStop surged on heavy volume, with investor Michael Burry announcing he is buying shares, expecting the stock to trade at one times tangible book value and net asset value.
• 🧠 Burry expressed belief in CEO Ryan Cohen's strategy for deploying capital over the long term, not relying on a short squeeze.

Key Stock Decliners

• 🔒 Booze Allen Hamilton fell over 8% after the US Treasury Department canceled $21 million in contracts due to the company's failure to protect taxpayer data, including President Trump's tax returns.
• 📉 The Treasury cited a former employee's felony charges for leaking records, including sensitive tax information.
• 💼 Trade Desk dropped more than 7% following the termination of its Chief Financial Officer, Alex Kayyal, over the weekend.
• 💊 Revolution Medicines shares plunged 17% after the Wall Street Journal reported that Merck ended talks to acquire the oncology company.
• 📊 Bloomberg Intelligence noted that the end of deal talks refocuses attention on Revolution Medicines' valuation, which had already risen 48% year-to-date.